武汉科前生物股份有限公司 独立萱事候选人声明与承诺 本人罗知,已充分了解并同意由提名人武汉科前生物股份有 限公司董事会提名为武汉科前生物股份有限公司第四届董事会 独立董事候选人。本人公开声明,本人具备独立董事任职资格, 保证不存在任何影响本人担任武汉科前生物股份有限公司独立 董事独立性的关系,具体声明并承诺如下: 一、本人具备上市公司运作的基本知识,熟悉相关法律、行 政法规、部门规章及其他规范性文件,具有五年以上法律、经济 会计、财务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求: (一)《中华人民共和国公司法》等关于董事任职资格的规 定; (二)《中华人民共和国公务员法》关于公务员兼任职务的 规定(如适用); (三)中国证监会《上市公司独立董事管理办法》和上海证 券交易所自律监管规则有关独立董事任职资格和条件的相关规 定; (六)中共中央纪委、教育部、监察部《关于加强高等学校 反腐倡廉建设的意见》的相关规定(如适用); (七)中国人民银行《股份制商业银行独立董事和外部监事 制度指引》等的相关规定(如适用): (八)中国证监会《证券基金经营机构 ...

证券代码：688526 证券简称：科前生物 公告编号：2025-030 武汉科前生物股份有限公司 关于拟与华中农大签订合作研发协议暨关联交易的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 关联交易简要内容：武汉科前生物股份有限公司（下称"科 前生物"或"公司"）拟与华中农业大学（下称"华中农大"）签订 "猪支原体肺炎、猪流感（H1N1、H3N2）二联灭活疫苗（XJ03 株+HN 株+SD 株）"联合开发协议书，双方自行承担其研究过程中在实验室 开展的各类试验的试验经费，合作研发项目产生的技术成果及知识产 权归公司及华中农大共同所有； 本次交易构成关联交易，不构成《上市公司重大资产重组管 理办法》规定的重大资产重组； 本次关联交易实施不存在重大法律障碍； 本次关联交易已经公司第四届董事会独立董事 2025 年第四次 会议、第四届董事会第十一次会议及第四届监事会第十次会议审议通 过，本事项无需提交股东大会审议。 风险提示：本次合作研发属于新技术研究开发，产品是否能 够研制成功、产品上市时间 ...

证券代码：688526 证券简称：科前生物 公告编号：2025-032 武汉科前生物股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 网络投票系统：上海证券交易所股东大会网络投票系统 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 26 日 14 点 00 分 召开地点：湖北武汉东湖新技术开发区高新二路 419 号科前生物二楼会议 室 （五） 网络投票的系统、起止日期和投票时间。 网络投票起止时间：自2025 年 6 月 26 日 至2025 年 6 月 26 日 股东大会召开日期：2025年6月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时 ...

二、监事会会议审议情况 经与会监事审议，作出决议如下： 一、审议通过《关于公司拟与华中农大签订合作研发协议暨 关联交易的议案》； 监事会认为：公司本次签订合作研发协议暨关联交易符合公 司整体发展方向，本次关联交易的审批程序合法合规，不存在损 害公司及股东利益的情形。 证券代码：688526 证券简称：科前生物 公告编号：2025-029 武汉科前生物股份有限公司 第四届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、 监事会会议召开情况 武汉科前生物股份有限公司（下称"公司"）于 2025 年 6 月 10 日以通讯表决的形式召开第四届监事会第十次会议（下称 "本次会议"）。本次会议通知于 2025 年 6 月 5 日以邮件、电 话的方式向各位监事发出，本次会议由监事会主席吴斌先生主持， 本次会议应参与表决监事 3 人，实际参与表决监事 3 人。本次会 议的召集、召开程序均符合《公司法》、《证券法》等法律、法 规和规范性文件以及《公司章程》的规定。 表决结果：同意 3 票、反对 0 票、弃权 ...

北京 BEIJING · 上海 SHANGHAI · 深圳| SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:武汉科前生物股份有限公司 北京市嘉源律师事务所 关于武汉科前生物股份有限公司差异化分红事项 的专项核查见见 北京市嘉源律师事务所 关于武汉科前生物股份有限公司差异化分红事项 的专项核查意见 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 二〇二五年五月 受武汉科前生物股份有限公司(以下简称"公司")委托,北京市嘉源律师 事务所〈以下简称"本所"）就公司 2024 年度利润分配涉及的差异化分红〈以 下简称"本次差异化分红"）相关事项出具本核查意见。 本核查意见依据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")、《上市公司股份回购 规则》（以下简称"《股份回购规则》"）、《上海证券交易所股票上市规则》 (以下简称"《上市规则》"）、《上海证券交易所上市公司自律监管指引第 7 号 -- 回购股份》(以下简称"《自律监管指引第 7 号》")以及《武汉科前生 物股份有限公司章程》(以下简 ...

证券代码：688526 证券简称：科前生物 公告编号：2025-028 武汉科前生物股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/13 | 2025/6/16 | 2025/6/16 | 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户除外）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，公司回购专用证券账户中的股份不享有股东会表 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.43元（含税） 相关日期 一、 通过分配方案的股东大会届次和日期 本次利润分配预案经公司2025年 5月 19 日的2024年年度股东大会审议通 ...

Summary of Conference Call on Pet Industry and Companies Industry Overview - The pet industry is experiencing rapid growth, with an annual compound growth rate of approximately 10% driven by increasing pet ownership and the rising penetration of pet food products [2][10] - The pet medical market is projected to reach 80-90 billion by 2025, making it the second-largest segment after pet food [10] Key Companies and Their Performance 1. Guibao Pet - Guibao Pet's self-owned brand has shown strong performance, with revenue of approximately 3.5 billion, accounting for nearly 70% of total revenue, and a net profit margin of 12% [1][4] - The high-end cat food brand, Fliegate, achieved a growth rate of 100% last year and maintained the same growth rate in Q1 of this year [4] - Guibao is expected to become a leading enterprise with projected revenues nearing 25 billion and net profits around 5 billion in the medium to long term [1][4] 2. Zhongchong Co., Ltd. - Zhongchong Co., Ltd. experienced a significant growth of nearly 200%-300% from its previous low, with total revenue from its three domestic brands (Wangpi, Lingxian, and ZIP) reaching 1.4 billion last year [5] - The company aims for overseas revenue of 400 million this year, maintaining a growth rate of 50% [5][6] - The net profit margin for its North American subsidiary is reported to be between 15%-20% [6] 3. Petty Co., Ltd. - Petty's overseas business accounts for a significant portion of its operations, with a focus on exports to the U.S. [8] - Domestic revenue was approximately 290 million last year, with a target of 400-450 million this year, reflecting a growth of over 40% [9] - The company is adjusting its product lines and plans to launch new baked grain products in Q2 and Q3 [8][9] Market Dynamics and Future Outlook - The pet medical sector is characterized by a lack of dominant players, with foreign brands leading in pharmaceuticals and vaccines, indicating substantial room for domestic companies to grow [11][12] - The average medical expenses for pets have doubled due to increasing age, leading to a rigid demand for medical services [10] - Companies like Ruipuhua and KQ Bio are recommended for their comprehensive industry layouts and potential for growth in the pet medical field [13][15] Additional Insights - The overall pet industry is expected to continue expanding, with self-owned brands focusing on product innovation to enhance profitability [2] - The competitive landscape in the pet medical sector is still developing, with many local companies poised to capture market share as the industry matures [12] - Other companies to watch include Baisha Technology, Biological Shares, and Zhongmu Shares, which have varying degrees of involvement in the pet medical sector [18]

Group 1 - Hongjing Technology signed a service contract for an intelligent computing project with a total amount of 597 million yuan, valid for 5 years [1] - Weifu High-Tech's subsidiary invested 220 million yuan to establish a joint venture with Shanghai Baolong Automotive Technology [2] - Zhongshan Public received approval for the registration of short-term financing bonds amounting to 2 billion yuan and medium-term notes of 3 billion yuan [3] Group 2 - Lianhua Technology established a venture capital fund with a total commitment of 200 million yuan, contributing 100 million yuan as a limited partner [4] - Changan Technology's shareholder signed an agreement to transfer 6.27% of the company's shares to Hefei State Capital Venture Investment [6] - Hangzhou Garden announced a cash dividend of 0.5 yuan per 10 shares, totaling 6.62 million yuan [8] Group 3 - Huamao Technology plans to acquire 100% equity of Fuchuang Youyue, leading to a temporary suspension of its stock [9] - Zhuojin Co. won a bid for a soil remediation project in Hefei with a contract value of 67.68 million yuan [10] - Shanghai Pharmaceuticals received FDA approval for two drugs, enhancing its product portfolio [10] Group 4 - Fuxing Pharmaceutical's senior vice president resigned for personal reasons [12] - Baolong Technology's subsidiary plans to invest 180 million yuan in a joint venture [13] - ST Zhongdi intends to utilize surplus funds from a project company, with a maximum of 106 million yuan [14] Group 5 - Nanchao Food reported a significant decline in net profit for April, down 82.14% year-on-year [16] - Changshan Pharmaceutical received a drug registration certificate in Belarus for a new product [18] - Nanshan Aluminum established a wholly-owned subsidiary for photovoltaic energy projects with an investment of 5 million yuan [20] Group 6 - Bozhong Precision announced the resignation of a director and deputy general manager [22] - Xinjiang Jiaojian won a bid for a highway construction project valued at 451 million yuan [23] - Guangzhou Restaurant declared a cash dividend of 0.48 yuan per share, totaling 273 million yuan [25] Group 7 - Weili Medical's subsidiary obtained a medical device operating license, allowing it to engage in wholesale activities [27] - New Australia Co. announced a cash dividend of 0.3 yuan per share, totaling 219 million yuan [28] - Lianhua Technology's subsidiary entered the new third board innovation layer [29] Group 8 - Huaxi Energy's chairman resigned due to personal reasons [31] - Yipin Hong plans to use up to 500 million yuan of idle funds for cash management [33] - Shouhua Gas intends to purchase bauxite resources through market means [34] Group 9 - Jincheng signed a service agreement for underground mining operations at the Komakau Copper Mine, valued at approximately 805 million USD [34] - Wanrun New Energy signed a supply contract with CATL for lithium iron phosphate products, with a total supply of about 1.32 million tons [35] - Weili plans to transfer 100% equity of a subsidiary to Chengfa Environment for 100 million yuan [36] Group 10 - Zhenlei Technology's subsidiary received government subsidies of 2.21 million yuan, positively impacting profits [38] - Weir shares plan to change their name to "Haowei Group" to reflect strategic direction [39] - YTO Express reported a revenue increase of 16.32% in April, totaling 5.755 billion yuan [39]

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

证券代码：688526 证券简称：科前生物 公告编号：2025-025 武汉科前生物股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 5 月 19 日 （二） 股东会召开的地点：湖北武汉东湖新技术开发区高新二路 419 号科前生 物二楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 57 | | --- | --- | | 普通股股东人数 | 57 | | 2、出席会议的股东所持有的表决权数量 | 343,728,273 | | 普通股股东所持有表决权数量 | 343,728,273 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 74.0927 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 74.0927 | 注 ...